UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

The oncologist (Dayton, Ohio), 2021-01, Vol.26 (1), p.e164-e172

2021

Volltextzugriff (PDF)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health

The oncologist (Dayton, Ohio), 2021-10, Vol.26 (10), p.e1786-e1799

2021

Volltextzugriff (PDF)

US Food and Drug Administration regulatory updates in neuro-oncology

Journal of neuro-oncology, 2021-07, Vol.153 (3), p.375-381

2021

Volltextzugriff (PDF)

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Nature reviews. Clinical oncology, 2021-03, Vol.18 (3), p.129-130

2021

Volltextzugriff (PDF)

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

Circulation (New York, N.Y.), 2019-03, Vol.139 (13), p.e579-e602

2019

Volltextzugriff (PDF)

CNS metastases in breast cancer: old challenge, new frontiers

Clinical cancer research, 2013-12, Vol.19 (23), p.6404-6418

2013

Volltextzugriff (PDF)

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

Journal of clinical oncology, 2017-11, Vol.35 (33), p.3760-3773

2017

Volltextzugriff (PDF)

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Clinical cancer research, 2021-04, Vol.27 (7), p.1850-1854

2021

Volltextzugriff (PDF)

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

Clinical cancer research, 2020-08, Vol.26 (16), p.4180-4185

2020

Volltextzugriff (PDF)

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2021-02, Vol.26 (2), p.139-146

2021

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Clinical cancer research, 2018-08, Vol.24 (15), p.3486-3491

2018

Volltextzugriff (PDF)

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Drug resistance updates, 2012-02, Vol.15 (1), p.50-61

2012

Volltextzugriff (PDF)

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action

The oncologist (Dayton, Ohio), 2018-08, Vol.23 (8), p.874-878

2018

Volltextzugriff (PDF)

Patient‐Friendly Language to Facilitate Treatment Choice for Patients with Cancer

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.1011-1012

2019

Volltextzugriff (PDF)

Methodology for Good Machine Learning with Multi‐Omics Data

Clinical pharmacology and therapeutics, 2024-04, Vol.115 (4), p.745-757

2024

Volltextzugriff (PDF)

Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature

Vascular medicine (London, England), 2021-10, Vol.26 (5), p.526-534

2021

Volltextzugriff (PDF)

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1225-1231

2018

Volltextzugriff (PDF)

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

Anti-cancer agents in medicinal chemistry, 2010-10, Vol.10 (8), p.625-633

2010

Volltextzugriff (PDF)

Myocarditis in the Setting of Cancer Therapeutics

Circulation (New York, N.Y.), 2019-07, Vol.140 (1), p.80-91

2019

Volltextzugriff (PDF)

21st Century Cardio-Oncology

JACC. Basic to translational science, 2016-08, Vol.1 (5), p.386-398

2016

Volltextzugriff (PDF)

Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System

Journal of oncology pharmacy practice, 2020-06, Vol.26 (4), p.923-928

2020

Volltextzugriff (PDF)

Why do phase III clinical trials in oncology fail so often?

JNCI : Journal of the National Cancer Institute, 2012-04, Vol.104 (8), p.568-569

2012

Volltextzugriff (PDF)

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

Journal of clinical oncology, 2022-10, Vol.40 (30), p.3489-3500

2022

Volltextzugriff (PDF)

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

The lancet oncology, 2020-02, Vol.21 (2), p.250-260

2020

Volltextzugriff (PDF)

US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer

Journal of clinical oncology, 2023-06, Vol.41 (18), p.3456-3457

2023

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(113)

Publikationsform

Artikel
(134)

Sprache

Englisch
(134)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(84)
Science & Technology
(84)
Oncology
(77)
Humans
(64)
Female
(37)
United States
(27)
United States Food And Drug Administration
(23)
Adult
(18)
Breast Neoplasms - Drug Therapy
(18)
Drug Approval
(17)
Male
(15)
Aged
(14)
Antineoplastic Agents - Therapeutic Use
(13)
Middle Aged
(13)
Treatment Outcome
(12)
Breast Cancer
(11)
Breast Neoplasms - Pathology
(11)
Clinical Trials
(11)
Aged, 80 And Over
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health

US Food and Drug Administration regulatory updates in neuro-oncology

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

CNS metastases in breast cancer: old challenge, new frontiers

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action

Patient‐Friendly Language to Facilitate Treatment Choice for Patients with Cancer

Methodology for Good Machine Learning with Multi‐Omics Data

Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

Myocarditis in the Setting of Cancer Therapeutics

21st Century Cardio-Oncology

Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System

Why do phase III clinical trials in oncology fail so often?

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer

Suchergebnisse filtern